"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2003 | 5 | 1 | 6 |
| 2004 | 6 | 3 | 9 |
| 2005 | 3 | 1 | 4 |
| 2006 | 5 | 2 | 7 |
| 2007 | 6 | 4 | 10 |
| 2008 | 9 | 2 | 11 |
| 2009 | 4 | 1 | 5 |
| 2010 | 6 | 2 | 8 |
| 2011 | 11 | 9 | 20 |
| 2012 | 4 | 5 | 9 |
| 2013 | 11 | 12 | 23 |
| 2014 | 10 | 6 | 16 |
| 2015 | 8 | 7 | 15 |
| 2016 | 19 | 6 | 25 |
| 2017 | 9 | 15 | 24 |
| 2018 | 18 | 9 | 27 |
| 2019 | 5 | 8 | 13 |
| 2020 | 5 | 10 | 15 |
| 2021 | 5 | 7 | 12 |
| 2022 | 1 | 13 | 14 |
| 2023 | 2 | 13 | 15 |
| 2024 | 8 | 11 | 19 |
| 2025 | 8 | 13 | 21 |
| 2026 | 8 | 4 | 12 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenstr?m macroglobulinemia. Blood. 2026 May 14; 147(20):2298-2314.
-
Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea. Blood. 2026 May 07; 147(19):2215-2225.
-
NTRK Gene Fusions: A Compendium of Fusion Partners and Tumor Types. JCO Precis Oncol. 2026 May; 10(5):e2501150.
-
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstr?m macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. Lancet Haematol. 2026 May; 13(5):e284-e296.
-
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. Blood Adv. 2026 Apr 14; 10(7):2441-2451.
-
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenstr?m Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. Am J Hematol. 2026 May; 101(5):1045-1055.
-
Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case Series. Adv Ther. 2026 Apr; 43(4):1380-1383.
-
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease. Nat Aging. 2026 Mar; 6(3):626-635.
-
Nilotinib-Induced Retinal Artery Thrombosis in a Patient With Chronic Myeloid Leukaemia: A Rare Case. Cancer Rep (Hoboken). 2026 Feb; 9(2):e70501.
-
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis. Curr Med Res Opin. 2025 Dec; 41(12):2323-2338.